MARKET

NPCE

NPCE

NeuroPace Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.15
+0.14
+0.67%
After Hours: 20.00 -1.15 -5.44% 17:24 05/07 EDT
OPEN
20.94
PREV CLOSE
21.01
HIGH
22.17
LOW
20.75
VOLUME
106.43K
TURNOVER
--
52 WEEK HIGH
27.38
52 WEEK LOW
20.25
MARKET CAP
489.44M
P/E (TTM)
--
1D
5D
1M
3M
1Y
5Y
Success of team-selling model has Baird seeing more upside in healthcare equipment maker
After a post-earnings rally yesterday, one healthcare equipment company reached up and touched $90/share, for just a minute - and "stocks that go to $90 tend to go to $100,"
Seekingalpha · 04/29 23:33
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27)
Benzinga · 04/28 11:26
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26)
Benzinga · 04/27 11:41
Monday 4/26 Insider Buying Report: NPCE, ODC
MarketNewsVideo.com · 04/26 14:52
Zymergen and 2 Other IPOs Made Strong Market Debuts Thursday
Knowbe4 jumped nearly 51% in its market debut, while NeuroPace was up nearly 47% and Zymergen rose more than 21%.
Barrons.com · 04/22 20:55
DJ NeuroPace Shares Jump in Trading Debut After Upsized IPO >NPCE
Dow Jones · 04/22 16:59
DJ Zymergen Leads 3 IPOs Making Their Market Debut Today -- Barrons.com
Dow Jones · 04/22 15:13
NeuroPace Soars 38% in Nasdaq Debut
MT Newswires · 04/22 13:58
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Learn about the latest financial forecast of NPCE. Analyze the recent business situations of NeuroPace Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.95%
Healthcare Equipment & Supplies
+0.66%
Key Executives
Chief Financial Officer/Vice President - Finance/Vice President - Administration/Primary Contact
Rebecca Kuhn
Vice President/Director of Sales
Mark Saxton
Vice President/Director of Marketing
Chi Nguyen
Vice President
Isabella Abati
Other
Martha Morrell
No Data
About NPCE
Neuropace, Inc. is a commercial-stage medical device company. The Company is focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. The Company’s novel and differentiated RNS System is the brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. Its two other neuromodulation devices includes Vagus Nerve Stimulation (VNS) and Deep Brain Stimulation (DBS). The VNS System provides scheduled extracranial stimulation delivered from a pectorally implanted pulse generator with the lead tunneled under the skin to the left vagus nerve in the neck next to the carotid artery. The DBS System relies on bilaterally implanted intracranial electrodes that are placed in each anterior thalamic nucleus, each located deep in the brain.

Webull offers kinds of Neuropace Inc stock information, including NASDAQ:NPCE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NPCE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NPCE stock methods without spending real money on the virtual paper trading platform.